Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Kim N. Chi,Simon Chowdhury,Anders Bjartell,Byung Ha Chung,Andrea Juliana Pereira de Santana Gomes,Robert Given,Alvaro Juarez-Soto,Axel S. Merseburger,Mustafa Ozguroglu,Hirotsugu Uemura,Dingwei Ye,Spyros Triantos,Suneel Mundle,Sharon Anne McCarthy,Julie S. Larsen,Weili Sun,Katherine Bevans,Ke Zhang,Nibedita Bandyopadhyay,Neeraj Agarwal

Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

2021

11Background: TITAN evaluated APA or PBO added to ADT in pts with mCSPC. Pts with high- and low-volume disease, prior docetaxel, prior treatment for localized disease, and prior ADT (≤ 6 mos) were ...

Keywords:

Urology
Apalutamide
Placebo
in patient
Castration-sensitive prostate cancer
Androgen deprivation therapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations